Improved candidate drug mining for Alzheimer's disease
Yu-Huei Cheng1, Li-Yeh Chuang2, Hsueh-Wei Chang3
1Department of Digital Content Design and Management, Toko University, Chiayi 613, Taiwan.
Biomed Research International
|April 11, 2014
Summary
This study enhances pharmacogenomics for Alzheimer's disease (AD) by improving how we search databases. New methods identify more genes linked to AD and its drugs, aiding personalized medicine.
Area of Science:
- Pharmacogenomics
- Neuroscience
- Genetics
Background:
- Alzheimer's disease (AD) is a leading cause of dementia in older adults.
- Current antidementia drug therapies show limited effectiveness.
- Single nucleotide polymorphisms (SNPs) are emerging as key markers for personalized medicine.
Purpose of the Study:
- To address the insufficiency of current pharmacogenomic databases for Alzheimer's disease.
- To improve the identification of genes associated with AD and related drug responses.
- To enhance the application of pharmacogenomics in personalized medicine for AD.
Main Methods:
- Utilized approximate string matching techniques.
- Employed data mining approaches for enhanced database searching.
- Integrated information from multiple pharmacogenomic databases.
Main Results:
- Successfully identified a greater number of genes linked to AD and AD-related drugs compared to previous methods.
- Demonstrated improved searching capabilities within pharmacogenomic databases.
- Validated the effectiveness of the developed computational approach.
Conclusions:
- The improved search methodology enhances the identification of pharmacogenomic markers for Alzheimer's disease.
- This advancement holds significant potential for advancing personalized medicine in AD treatment.
- Further development in pharmacogenomic data integration is crucial for clinical applications.
More Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:26Drug Discovery: Overview
10.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.4K
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
926
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
926